Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home
- Registration Number
- NCT04685512
- Lead Sponsor
- University Hospital, Caen
- Brief Summary
COVID-19 pandemic is currently affecting the globe. To date, there is no effective oral therapy against SARS-CoV2 infection. The investigators propose to test as a repurposing drug combination, a short course of tenofovir disoproxil and emtricitabine (TDF/FTC), as a proof-of-concept randomized open-label study to test its viral efficacy against SARS-CoV2.
- Detailed Description
The SARS-CoV2 pandemic is causing morbidity and mortality. There is no cure. Remdesivir is a nucleotide analogue that has demonstrated its efficacy in vitro against SARS-CoV2 and in humans (shorten symptoms duration by 2 days without improving survival), but it is used parenterally. TDF belongs to the same therapeutic class, represents a promising avenue of research. TDF/FTC demonstrated in vivo efficacy against SARS-CoV2 in preclinical animal models and its use is associated with reduced risk of SARS-CoV2 infection in 2 large cohorts of HIV infected patients.The objective of this work is to evaluate the anti-viral efficacy of the TDF/FTC combination in short course in patients infected with SARS-CoV2 on an outpatient basis.
The investigators propose a multicenter, open-label, phase 2B/3 randomized trial of a 7-day treatment with TDF / FTC (2 tablets on Day-1 then 1 tablet / day for 6 days) according to the dosage used in pre-exposure prophylaxis for HIV. This study should include 60 outpatients (Phase 2B) and 120 additional outpatients (Phase III) who were diagnosed with SARS-CoV2 positive and with no contraindication to TDF / FTC and without criteria for hospitalization. The primary endpoint of the phase 2B will be the SARS-CoV2 antiviral efficacy quantified by RT-PCR nasopharyngeal sample Ct increase on Day-4 compared to baseline. The primary endpoint of the phase 3 will be the rate of non-contagious PCR on Day-4 from a nasopharyngeal sample. Secondary endpoints will be tolerance, symptoms resolution, percentage of hospitalization and the rate of non-contagious PCR on Day-7 from a nasopharyngeal sample.
The investigators hypothesize that compared to no treatment, treatment with TDF/FTC reduces at Day-4:
* SARS-CoV2 viral load corresponding to a 4-point +/-5 increase in Ct (Phase 2B)
* contagious carriage from 80% to 60% (Phase 3).
The AR0-CORONA investigators hope, through this study, to be able to validate an anti-viral treatment making it possible to reduce the duration of contagiousness and thus contribute to attenuating the R0 of recently infected patients carrying SARS-CoV2 who are isolated at home.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
- Patients 18 years and over
- SARS-CoV2 Infection confirmed by PCR
- Patients who do not require immediate hospitalization
- Signed informed consent
Non-Inclusion criteria:
- Patients with HIV or Hepatitis B
- Symptoms suggestive of a SARS-CoV2 infection that has been progressing for more than 7 days
- Asympomatic patients with unknown date of infection or date of infection>7 days
- Chronic HCV infection
- Contraindication to the use of TDF/FTC
- Hypersensitivity to tenofovir, to emtricitabine or to any of the excipients (especially lactose)
- Glomerular filtration rate <80mL / min
- Recent (less than 7 days) or concomitant use of NSAIDs or other nephrotoxic drugs (antiinfectives, immunosuppressants, allopurinol, lithium
- need for hospitalization for contemporary decompensation of a comorbidity
- need for hospitalization due to SARS-CoV2 infection:
- Capillary oximetry less than 95%
- clinical evaluation by the investigating doctor leading to hospitalization
- Pregnant or breastfeeding women
- Diagnosis of pregnancy during treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TDF / FTC tenofovir disoproxil and emtricitabine 2 tablets on Day-1 then 1 tablet/day for 6 days
- Primary Outcome Measures
Name Time Method Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28 Day-4 after the start of study Nasopharyngeal swab performed at day-4 with RT-PCR for SARS-CoV2
Phase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA) Day-4 after the start of study Nasopharyngeal swab performed at baseline and day-4 with RT-PCR for SARS-CoV2
- Secondary Outcome Measures
Name Time Method Phase 3: Symptoms score From the start of the study to Day-7 Self-reported COVID-19 related symptoms
Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28 Day-7 after the start of study Nasopharyngeal swab performed at day-7 with RT-PCR for SARS-CoV2
Phase 2B/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] From the start of the study to Day-7 Number of adverse events according to the CTCAE grade
Phase 3: Proportion of secondary hospitalization Day-15 Assessed by investigators up to day-15
Trial Locations
- Locations (2)
Caen University Hospital
🇫🇷Caen, Calvados, France
Regional Hospital
🇫🇷Orléans, France